Suven Life Sciences Hits Full Mark: Ropanicant Trial Reaches 100% Enrollment, Lifts MDD Hopes

Trial Milestone Achieved

Suven Life Sciences, a clinical-stage biopharmaceutical firm focused on CNS disorders, has reached full patient enrollment in its pivotal Phase-2b study of Ropanicant (SUVN-911). This randomized, double-blind, placebo-controlled trial evaluates the drug's efficacy and safety over six weeks, using the Montgomery-Åsberg Depression Rating Scale (MADRS) in MDD patients. Building on rapid prior progress—25% in two months, over 55% in three—the complete enrollment underscores high investigator and patient interest amid unmet needs in depression treatment.​

 

Key Highlights

This milestone boosts Suven's pipeline momentum in CNS innovation.

 

Sources: Suven Life Sciences, Marketscreener, ClinicalTrials.gov, NSE India